支氣管擴張市場－全球及區域分析：按國家、地區分類－分析與預測（2025-2035）

全球支氣管擴張市場分析與預測（2025-2035）

支氣管擴張是一種慢性呼吸系統疾病，肺部的支氣管（氣道）會異常且不可逆地擴張。

氣道擴張會導致黏液排放障礙、性行為感染和肺部發炎。這種情況可導致慢性咳嗽、黏液分泌過多和頻繁的肺部感染疾病。支氣管擴張可作為原發性疾病出現，也可繼發於其他疾病，例如囊腫纖維化、慢性阻塞性肺病（COPD）和免疫力缺乏。它也可能由反覆呼吸道感染疾病、結核病或吸入異物引起。

支氣管擴張症市場成長的促進因素包括全球盛行率上升、公眾意識增強、治療方法進步以及人口老化導致呼吸系統疾病易感人群增加。慢性呼吸系統疾病，例如慢性阻塞性肺病（COPD）、囊腫纖維化和自體免疫疾病，常常導致支氣管擴張症，使得需要有效治療以控制症狀和預防疾病進展的患者群體日益壯大。全球人口老化是支氣管擴張症盛行率上升的主要原因。此外，人們逐漸認知到支氣管擴張症是慢性呼吸症狀的常見原因，這提高了診斷率，從而推動了對控制發炎、感染疾病和黏液分泌的治療方法的需求。例如，COPD是支氣管擴張症的主要危險因素，其盛行率的上升促使人們採用噻托溴銨（思力華）和Fluticasone等長期吸入療法來控制氣流阻塞並改善患者預後。

此外，近年來支氣管擴張的治療模式發生了顯著變化，從症狀治療轉向更有針對性的疾病修正治療。大環內酯類抗生素（例如阿奇黴素）現在被常規用於減少病情加重、預防感染疾病和改善患者的生活品質。

此外，生物製藥和免疫調節劑的研發為支氣管擴張的治療提供了新的可能性，尤其適用於合併自體免疫疾病或發炎性疾病的患者。這些治療方法可針對特定的免疫通路，旨在減輕發炎並預防肺損傷。人們對生物製藥（例如抗TNF-α製劑和白細胞介素抑制劑）的作用越來越感興趣，這些藥物有望徹底改變支氣管擴張相關慢性發炎患者的治療方式。

儘管治療方法取得了進展，但挑戰仍然存在。例如，生物製藥和吸入療法的高昂費用可能會限制患者獲得治療的機會，尤其是在低收入國家的醫療體系中。此外，由於支氣管擴張是一種需要長期管理的慢性疾病，治療的連續性仍然是一個重要問題。確保患者堅持處方治療方案，尤其是在涉及複雜的吸入療法和每日服用抗生素的情況下，仍然是有效治療的一大障礙。

支氣管擴張症作為一種獨特的臨床疾病的認知，正為更精準的醫療方法鋪平道路。這一趨勢的驅動力源於基因譜分析和生物標記發現技術的進步，這些技術使得針對特定患者特徵的標靶治療成為可能。特別是，針對囊腫纖維化相關性支氣管擴張症和自體免疫支氣管擴張症的個人化療法有望獲得市場認可。生物製藥和免疫調節劑是個人化醫療中最有前景的治療選擇之一，它們針對參與氣道發炎和損傷的特定路徑。

本報告對全球支氣管擴張市場進行了分析，並概述了市場狀況、區域趨勢以及參與該市場的公司的概況。

目錄

執行摘要

第1章 全球支氣管擴張市場：產業展望

• 市場概覽
• 支氣管擴張的區域流行病學分析
• 監管狀態
• 主要趨勢
• 臨床試驗分析
• 市場動態
  • 影響分析
  • 市場促進因素
  • 市場約束
  • 市場機遇

2. 全球支氣管擴張市場（按地區分類，單位：百萬美元），2023-2035年

• 北美洲
  • 市場動態
  • 市場規模及預測
• 歐洲
  • 市場動態
  • 市場規模及預測
• 亞太地區
  • 市場動態
  • 市場規模及預測

3. 全球支氣管擴張市場－競爭格局與公司概況

• 關鍵策略和發展（按公司分類）
  • 資金籌措活動
  • 併購
  • 監管部門核准
  • 夥伴關係、合作與業務拓展
• 公司簡介
  • Insmed Incorporated
  • AstraZeneca
  • ZAMBON COMPANY SPA
  • Chiesi Farmaceutici SpA
  • Armata Pharmaceuticals
  • Merck
  • Sanofi
  • Boehringer Ingelheim International GmbH
  • 其他

第4章調查方法

Global Bronchiectasis Market, Analysis and Forecast: 2025-2035

Bronchiectasis is a chronic respiratory condition characterized by the abnormal and irreversible dilation of the bronchial tubes (airways) in the lungs. This widening of the airways leads to impaired mucus clearance, recurrent infections, and inflammation of the lungs. The condition can result in chronic cough, excessive mucus production, and frequent lung infections. Bronchiectasis may arise as a primary disease or be secondary to other conditions such as cystic fibrosis, chronic obstructive pulmonary disease (COPD), or immunodeficiency disorders. It can also result from recurrent respiratory infections, tuberculosis, or inhalation of foreign bodies.

The bronchiectasis market is driven by an increasing global prevalence of the condition, growing awareness, advancements in treatment modalities, and an aging population that is more susceptible to respiratory diseases. Chronic respiratory conditions like COPD, cystic fibrosis, and autoimmune disorders often lead to bronchiectasis, contributing to a growing patient base that requires effective treatments to manage symptoms and prevent disease progression. As the global population ages, the prevalence of bronchiectasis is rising. Moreover, the increasing recognition of bronchiectasis as a common cause of chronic respiratory symptoms is leading to higher diagnosis rates, fueling the demand for treatments that manage inflammation, infections, and mucus production. For instance, the increasing prevalence of COPD, a major risk factor for bronchiectasis, is driving the adoption of long-term inhaled therapies like tiotropium (Spiriva) and fluticasone to manage airflow obstruction and improve patient outcomes.

In addition, the treatment landscape for bronchiectasis has evolved significantly in recent years, shifting from symptomatic treatments to more targeted, disease-modifying therapies. Macrolide antibiotics (e.g., azithromycin) are now routinely used to reduce exacerbations, prevent infections, and improve quality of life for patients.

Also, the development of biologics and immunomodulators represents the next frontier for treating bronchiectasis, especially in patients with autoimmune or inflammatory conditions. These therapies aim to target specific immune system pathways, reducing inflammation and preventing lung damage. There is growing interest in the role of biologics such as anti-TNF-alpha agents and interleukin inhibitors, which could significantly change the management of patients with chronic inflammation in bronchiectasis.

Despite the advances in treatment, challenges remain, such as high costs associated with biologic therapies and inhaled treatments, which can limit access, particularly in lower-income healthcare systems. Additionally, treatment adherence remains a significant issue, as bronchiectasis is a chronic condition requiring long-term management. Ensuring that patients stick to prescribed regimens, especially when involving complex inhalation therapies or daily antibiotics, remains a barrier to effective treatment.

The growing recognition of bronchiectasis as a distinct clinical condition is opening the door to more precision medicine approaches. This trend is driven by advancements in genetic profiling and biomarker discovery, which allow for targeted treatments tailored to specific patient profiles. Personalized therapies, particularly those aimed at cystic fibrosis-related bronchiectasis and autoimmune-driven bronchiectasis, are expected to gain traction in the market. Biologics and immunomodulators are among the most promising treatment options in personalized medicine, targeting specific pathways involved in airway inflammation and damage.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Bronchiectasis Market: Industry Outlook

• 1.1 Market Overview
• 1.2 Epidemiological Analysis of Bronchiectasis, By Region
• 1.3 Regulatory Landscape
• 1.4 Key Trends
• 1.5 Clinical Trial Analysis
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Restraint
  • 1.6.4 Market Opportunities

2. Global Bronchiectasis Market, by Region, $Million, 2023-2035

• 2.1 North America
  • 2.1.1 Market Dynamics
  • 2.1.2 Market Sizing and Forecast
    • 2.1.2.1 North America Bronchiectasis Market, by Country
      • 2.1.2.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Market Dynamics
  • 2.2.2 Market Sizing and Forecast
    • 2.2.2.1 Europe Bronchiectasis Market, by Country
      • 2.2.2.1.1 Germany
      • 2.2.2.1.2 U.K.
      • 2.2.2.1.3 France
      • 2.2.2.1.4 Italy
      • 2.2.2.1.5 Spain
• 2.3 Asia-Pacific
  • 2.3.1 Market Dynamics
  • 2.3.2 Market Sizing and Forecast
    • 2.3.2.1 Asia-Pacific Bronchiectasis Market, by Country
      • 2.3.2.1.1 Japan

3. Global Bronchiectasis Market -Competitive Landscape and Company Profiles

• 3.1 Key Strategies and Development, by Company
  • 3.1.1 Funding Activities
  • 3.1.2 Mergers and Acquisitions
  • 3.1.3 Regulatory Approvals
  • 3.1.4 Partnerships, Collaborations and Business Expansions
• 3.2 Company Profiles
  • 3.2.1 Insmed Incorporated
    • 3.2.1.1 Overview
    • 3.2.1.2 Product Portfolio
    • 3.2.1.3 Target Customers
    • 3.2.1.4 Key Personnel
    • 3.2.1.5 Analyst View
  • 3.2.2 AstraZeneca
    • 3.2.2.1 Overview
    • 3.2.2.2 Product Portfolio
    • 3.2.2.3 Target Customers
    • 3.2.2.4 Key Personnel
    • 3.2.2.5 Analyst View
  • 3.2.3 ZAMBON COMPANY S.P.A.
    • 3.2.3.1 Overview
    • 3.2.3.2 Product Portfolio
    • 3.2.3.3 Target Customers
    • 3.2.3.4 Key Personnel
    • 3.2.3.5 Analyst View
  • 3.2.4 Chiesi Farmaceutici S.p.A
    • 3.2.4.1 Overview
    • 3.2.4.2 Product Portfolio
    • 3.2.4.3 Target Customers
    • 3.2.4.4 Key Personnel
    • 3.2.4.5 Analyst View
  • 3.2.5 Armata Pharmaceuticals
    • 3.2.5.1 Overview
    • 3.2.5.2 Product Portfolio
    • 3.2.5.3 Target Customers
    • 3.2.5.4 Key Personnel
    • 3.2.5.5 Analyst View
  • 3.2.6 Merck
    • 3.2.6.1 Overview
    • 3.2.6.2 Product Portfolio
    • 3.2.6.3 Target Customers
    • 3.2.6.4 Key Personnel
    • 3.2.6.5 Analyst View
  • 3.2.7 Sanofi
    • 3.2.7.1 Overview
    • 3.2.7.2 Product Portfolio
    • 3.2.7.3 Target Customers
    • 3.2.7.4 Key Personnel
    • 3.2.7.5 Analyst View
  • 3.2.8 Boehringer Ingelheim International GmbH
    • 3.2.8.1 Overview
    • 3.2.8.2 Product Portfolio
    • 3.2.8.3 Target Customers
    • 3.2.8.4 Key Personnel
    • 3.2.8.5 Analyst View
  • 3.2.9 Others

4. Research Methodology

List of Figures

• Figure: Bronchiectasis Market (by Scenario), $Million, 2024, 2030, and 2035
• Figure: Global Bronchiectasis Market, 2024 and 2035
• Figure: Global Bronchiectasis Market Key Trends, Impact Analysis, 2023-2035
• Figure: North America Bronchiectasis Market, $Million, 2023-2035
• Figure: Europe Bronchiectasis Market, $Million, 2023-2035
• Figure: Asia-Pacific Bronchiectasis Market, $Million, 2023-2035

List of Tables

• Table: Market Snapshot
• Table: Global Bronchiectasis Market Dynamics, Impact Analysis
• Table: Global Bronchiectasis Market (by Region), $Million, 2023-2035